Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
CCG-100602
Cat. No.:
OB0225LY-0044
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
CCG-100602 is a selective small molecule inhibitor that primarily targets the process of post-translational modification of certain proteins.
Synonym:
1207113-88-9; 1-[3,5-Bis(trifluoromethyl)benzoyl]-N-(4-chlorophenyl)piperidine-3-carboxamide; [3,5-Bis(trifluoromethyl)benzoyl]-N-(4-chlorophenyl)piperidine-3-carboxamide
CAS No.:
1207113-88-9
Compound CID:
46190808
Formula:
C21H17ClF6N2O2
Formula Weight:
478.82
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
CCG-100602 can be used to probe cell signaling, cell proliferation, and related disease models.
Library Information
Targets:
Rho; Ras
Pathways:
Cell cycle/Checkpoint; GPCR/G protein; MAPK; Rho/MRTF/SRF signaling
Plate Number:
AOCL-1
Plate Location:
e6
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
100 mg/mL; 208.85 mM
